Mallampati Score Is an Independent Predictor of Active Oxygen Therapy in Patients with COVID-19
Authors:
- Maciej DyrbuśMDMaciej Dyrbuś
- Aleksandra OraczewskaAOAleksandra Oraczewska
- Szymon SzmigielSSSzymon Szmigiel
- Szymon GawędaSGSzymon Gawęda
- Paulina KluszczykPKPaulina Kluszczyk
- Tomasz CyzowskiTCTomasz Cyzowski
- Marek JędrzejekMJMarek Jędrzejek
- Paweł DubikPDPaweł Dubik
- Michał KozłowskiMKMichał Kozłowski
- Sebastian KwiatekSKSebastian Kwiatek
- Beata CelińskaBCBeata Celińska
- Michał WitaMWMichał Wita
Open Access
- 24 May 2022
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (11) , 2958
Abstract
Mallampati score has been identified and accepted worldwide as an independent predictor of difficult intubation and obstructive sleep apnea. We aimed to determine whether Mallampati score assessed on the first patient medical assessment allowed us to stratify the risk of worsening of conditions in patients hospitalized due to COVID-19. A total of 493 consecutive patients admitted between 13 November 2021 and 2 January 2022 to the temporary hospital in Pyrzowice were included in the analysis. The clinical data, chest CT scan, and major, clinically relevant laboratory parameters were assessed by patient-treating physicians, whereas the Mallampati score was assessed on admission by investigators blinded to further treatment. The primary endpoints were necessity of active oxygen therapy (AOT) during hospitalization and 60-day all-cause mortality. Of 493 patients included in the analysis, 69 (14.0%) were in Mallampati I, 57 (11.6%) were in Mallampati II, 78 (15.8%) were in Mallampati III, and 288 (58.9%) were in Mallampati IV. There were no differences in the baseline characteristics between the groups, except the prevalence of chronic kidney disease (p = 0.046). Patients with Mallampati IV were at the highest risk of AOT during the hospitalization (33.0%) and the highest risk of death due to any cause at 60 days (35.0%), which significantly differed from other scores (p = 0.005 and p = 0.03, respectively). Mallampati IV was identified as an independent predictor of need for AOT (OR 3.089, 95% confidence interval 1.65–5.77, p < 0.001) but not of all-cause mortality at 60 days. In conclusion, Mallampati IV was identified as an independent predictor of AOT during hospitalization. Mallampati score can serve as a prehospital tool allowing to identify patients at higher need for AOT.Keywords
Funding Information
- Medical University of Silesia in Katowice (PCN-1-208/K/1/O)
This publication has 40 references indexed in Scilit:
- High-flow nasal cannula oxygenation utilization in respiratory failureEuropean Journal of Internal Medicine, 2019
- Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failureEuropean Respiratory Journal, 2017
- Pneumonia Severity Assessment Tools for Predicting Mortality in Patients with Healthcare-Associated Pneumonia: A Systematic Review and Meta-AnalysisRespiration, 2017
- High-Flow Nasal Cannula in Critically Ill Subjects With or at Risk for Respiratory Failure: A Systematic Review and Meta-AnalysisRespiratory Care, 2016
- Prediction of severe community-acquired pneumonia: a systematic review and meta-analysisCritical Care, 2012
- Validity of British Thoracic Society guidance (the CRB-65 rule) for predicting the severity of pneumonia in general practice: systematic review and meta-analysisBritish Journal of General Practice, 2010
- Physical Examination: Mallampati Score as an Independent Predictor of Obstructive Sleep ApneaSLEEP, 2006
- Impact of sleep on respiratory muscle function.2003
- A Prediction Rule to Identify Low-Risk Patients with Community-Acquired PneumoniaNew England Journal of Medicine, 1997
- A clinical sign to predict difficult tracheal intubation; a prospective studyCanadian Journal of Anesthesia/Journal canadien d'anesthésie, 1985